Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as a 370 MBq per vial injectable solution for intravenous use. It is used to assess myocardial perfusion and detect coronary artery disease in patients undergoing cardiac stress testing. The agent enables single‑photon emission computed tomography (SPECT) imaging to visualize blood flow distribution across the myocardium.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and procurement teams worldwide, ensuring reliable cold‑chain logistics and regulatory compliance for radiopharmaceuticals.

Myoview (tetrofosmin) is employed in cardiac imaging to evaluate myocardial blood flow and identify coronary artery disease.

- Myocardial perfusion imaging: provides detailed images of blood flow to the heart muscle at rest and during stress. - Detection of coronary artery disease: highlights regions with reduced perfusion indicating possible arterial blockages. - Stress cardiac imaging: assesses myocardial perfusion response to pharmacologic or exercise stress. - Evaluation of myocardial viability: helps determine viable versus scarred myocardial tissue for therapeutic planning.

Adverse reactions to Myoview are generally infrequent but may occur following intravenous administration of the radiopharmaceutical.

Common Side Effects: - Nausea: mild transient nausea reported in some patients. - Headache: occasional mild headache during or after the procedure. - Injection site pain: mild discomfort at the venipuncture site.

Serious or Rare Side Effects: - Anaphylactic reaction: rare severe allergic response requiring immediate medical attention. - Severe hypotension: uncommon drop in blood pressure following injection. - Radiation‑induced skin injury: very rare localized skin reaction at the injection site. - Cardiac arrhythmia: rare occurrence of abnormal heart rhythms. - Pulmonary embolism: extremely rare thrombotic event.

When using Myoview, several precautions should be observed to ensure patient safety and optimal image quality. - Pregnancy: avoid use unless clearly necessary, as fetal effects are unknown. - Breastfeeding: discontinue breastfeeding or consider alternative imaging, because radiotracer may be excreted in milk. - Renal impairment: assess kidney function, as reduced clearance may affect tracer distribution. - Allergies: screen for known hypersensitivity to technetium‑99m compounds. - Concomitant medications: inform the physician of drugs that may alter myocardial blood flow (e.g., vasodilators, beta‑blockers). - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with certain drugs or conditions that influence myocardial blood flow or radiotracer distribution.

Major Interactions (Avoid): - Vasodilators (e.g., nitroglycerin): may alter perfusion patterns and affect image interpretation. - Beta‑blockers: can blunt stress response, leading to false‑negative results. - Calcium channel blockers: may modify coronary flow and impact tracer uptake.

Moderate Interactions (Monitor Closely): - Caffeine‑containing products: can interfere with pharmacologic stress agents, reducing test accuracy. - Antidepressants (SSRIs): may affect heart rate response during stress testing. - Thyroid hormones: altered metabolism may influence radiotracer kinetics.